Published • loading... • Updated
NIQ Announces Third Quarter 2026 Results
The biopharmaceutical company posted $54.5 million in revenue and grant income, above Street estimates, while reporting a net loss of $14.7 million.
- On Thursday, November 12, 2026, CorMedix Therapeutics reported its third-quarter 2026 financial results, including a net loss of $14.7 million.
- Growth drivers identified for the company include a pending asset purchase and a recent FDA grant for a prophylaxis product.
- Sales of DefenCath contributed $17.2 million, with the remainder of the portfolio adding $37.3 million and adjusted EBITDA reaching $3.1 million.
- Management expects the Heron acquisition to effectively double annual revenue from other sources, noting the transaction is "immediately accretive to earnings" upon its planned closing.
- Following recent changes to the CMS reimbursement framework, the company suspended future revenue guidance and will defer updates until early next year.
Insights by Ground AI
86 Articles
86 Articles
Tioga PublishingReposted by 
Kosmo Online
Kosmo OnlineHealth In Tech Reports Third Quarter 2026 Financial Results
Contracted Revenue of $32.7 Million for the First Nine Months of 2026
·Pennsylvania, United States
Read Full Article
Coverage Details
Total News Sources86
Leaning Left15Leaning Right8Center29Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 29%
C 56%
15%
Factuality
To view factuality data please Upgrade to Premium
